Syntekabio Reports Q1 Revenue Surge, 5x Last Year’s Total

Syntekabio announced on Tuesday that it recorded consolidated revenue of KRW 860 million in the first quarter of 2025. This figure represents more than a fivefold increase compared to the company’s total revenue for the entire previous year.

The company explained that this performance signals Syntekabio’s transition into a phase of generating meaningful revenue.

Notably, this year marks the end of a grace period for designation as a “cautionary issue” under Korea Exchange rules. Companies failing to meet the KRW 3 billion annual revenue requirement are at risk of being labeled as such. The strong Q1 results are seen as alleviating much of the market’s concern in this regard.

Syntekabio has been steadily expanding its partnerships through joint research agreements and memoranda of understanding(MOU) with domestic and international pharmaceutical companies and biotechs, earning recognition for its technological competitiveness.

The company’s AI-based drug discovery platform forms the core of a differentiated technology portfolio, setting it apart from traditional biotech firms. Current projects include the development of a targeted protein degradation(TPD) inhibitor with a Boston-based biotech, an inflammatory bowel disease(IBD) treatment with Progenma Bio, and a pan-coronavirus therapeutic capable of treating both SARS and MERS in collaboration with Protico. The company is also engaged in cancer drug development with leading Korean pharmaceutical firms.

Syntekabio is additionally co-developing a pulmonary fibrosis treatment with Australia’s QIMR Berghofer Medical Research Institute and has partnered with Memorial Sloan Kettering Cancer Center(MSKCC), the largest cancer hospital in the United States, on multiple anti-cancer therapeutics targeting proprietary pathways.

“This quarter’s results demonstrate that our AI-driven technologies are translating into meaningful outcomes in the market,” a company spokesperson said. “We will continue to pursue significant contracts and research results to establish a stable revenue base and drive full-scale growth.”

SOURCE : https://pharm.edaily.co.kr/News/Read?newsId=04139366642168592&mediaCodeNo=257